Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
22.4 SEK | -3.86% | +17.52% | +57.97% |
Sales 2024 * | 52M 5M | Sales 2025 * | 393M 37.82M | Capitalization | 2.5B 241M |
---|---|---|---|---|---|
Net income 2024 * | -236M -22.71M | Net income 2025 * | -173M -16.64M | EV / Sales 2024 * | 40.6 x |
Net cash position 2024 * | 391M 37.64M | Net cash position 2025 * | 210M 20.22M | EV / Sales 2025 * | 5.83 x |
P/E ratio 2024 * |
-13.8
x | P/E ratio 2025 * |
-9.52
x | Employees | 26 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 86.03% |
Latest transcript on Vicore Pharma Holding AB
1 day | -3.86% | ||
1 week | +17.52% | ||
Current month | +1.82% | ||
1 month | +16.42% | ||
3 months | +56.21% | ||
6 months | +44.52% | ||
Current year | +57.97% |
Managers | Title | Age | Since |
---|---|---|---|
Ahmed Mousa
CEO | Chief Executive Officer | 40 | 23-09-08 |
Hans Jeppsson
DFI | Director of Finance/CFO | - | 16-12-31 |
Elin Rosendahl
CTO | Chief Tech/Sci/R&D Officer | - | 20-11-15 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 57 | 17-12-31 | |
Chairman | 66 | 17-12-31 | |
Michael Buschle
BRD | Director/Board Member | 64 | 22-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-06-05 | 22.4 | -3.86% | 277,729 |
24-06-04 | 23.3 | +1.30% | 535,623 |
24-06-03 | 23 | +4.55% | 749,049 |
24-05-31 | 22 | +15.18% | 1,414,509 |
24-05-30 | 19.1 | +0.21% | 254,212 |
Delayed Quote Nasdaq Stockholm, June 05, 2024 at 11:30 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+57.97% | 240M | |
+18.72% | 125B | |
+14.53% | 109B | |
-2.88% | 24.74B | |
+4.60% | 22.67B | |
-9.63% | 18.14B | |
-41.04% | 16.67B | |
-11.83% | 16.64B | |
+1.46% | 13.45B | |
+24.22% | 11.32B |
- Stock Market
- Equities
- VICO Stock